Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1958 1
1985 1
1986 6
1987 2
1989 2
1991 1
1992 2
1993 1
1996 1
1997 2
2005 1
2008 1
2011 1
2013 2
2014 1
2016 1
2017 1
2018 2
2019 1
2020 1
2021 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N, Fasching PA, Wuerstlein R, Degenhardt T, Lüftner D, Kates RE, Schumacher J, Räth P, Hoffmann O, Lorenz R, Decker T, Reinisch M, Göhler T, Staib P, Gluz O, Schinköthe T, Schmidt M; AGO-B WSG PreCycle investigators (see Appendix 1). Harbeck N, et al. Ann Oncol. 2023 Aug;34(8):660-669. doi: 10.1016/j.annonc.2023.05.003. Epub 2023 May 16. Ann Oncol. 2023. PMID: 37201751 Free article. Clinical Trial.
The Endocrine Treatment Landscape for Patients with HR+ HER2- Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy - A Real-World Analysis.
Nabieva N, Altmann F, Apel K, Baerens DT, Beha M, Belau A, Busch S, Guth D, Heinrich G, Kreiss-Sender J, Markmann S, Olbermann A, Oskay-Özcelik G, Schuback B, Steinfeld-Birg D, Quiering C, Kiss F, Kreuzeder J, Nuti P, Schilling J. Nabieva N, et al. Among authors: guth d. Geburtshilfe Frauenheilkd. 2023 Jul 18;83(9):1127-1137. doi: 10.1055/a-2100-0643. eCollection 2023 Sep. Geburtshilfe Frauenheilkd. 2023. PMID: 37942358 Free PMC article.
Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.
Metz M, Semsek D, Rogmans G, Hutzschenreuter U, Fietz T, Harde J, Zacharias S, Hielscher C, Lorenz A, Zahn MO, Guth D, Liebers S, Berghorn M, Grebhardt S, Matillon CD, Egerer G, Potthoff K. Metz M, et al. Among authors: guth d. Support Care Cancer. 2021 Nov;29(11):6633-6643. doi: 10.1007/s00520-021-06230-9. Epub 2021 May 6. Support Care Cancer. 2021. PMID: 33956213 Free PMC article. Clinical Trial.
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.
Harbeck N, Wrobel D, Zaiss M, Terhaag J, Guth D, Distelrath A, Zahn MO, Wuerstlein R, Lorenz A, Bartsch R, Breitenstein U, Schwitter M, Balic M, Jackisch C, Müller V, Rinnerthaler G, Schmidt M, Zaman K, Schinköthe T, Resch A, Valenti R, Lüftner D. Harbeck N, et al. Among authors: guth d. Breast Care (Basel). 2024 Feb;19(1):1-9. doi: 10.1159/000533657. Epub 2023 Oct 5. Breast Care (Basel). 2024. PMID: 38384488
38 results